Skip to main content
OpenTrials
Recruiting

NCT Number: NCT04740580

Glutathione, Brain Metabolism and Inflammation in Alzheimer's Disease

Alzheimer's disease (AD) is associated with significant, progressive cognitive decline. Key defects in mitochondrial fuel metabolism insulin resistance, inflammation and decreased brain glucose uptake are linked to AD. This trial will investigate the effects of supplementing glycine and N-acetylcysteine vs. alanine as placebo on these defects in AD, and examine the effects on cognition.

Recruiting

Interested in participating?

Request Info

Key information

Age range

55 year–85 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Early Phase 1

Primary location

Baylor College of Medicine

Houston, Texas, 77030, United States

Location status: Recruiting

Location contact

Rajagopal V Sekhar, MD

CONTACT

[email protected]

713-798-3908

About this study

Glutathione (GSH) deficiency, oxidative stress, mitochondrial dysfunction, insulin resistance and inflammation are linked to Alzheimer's disease (AD). In prior studies, investigators have shown that GSH deficiency contributes to mitochondrial impairment and oxidative stress, and that GSH deficiency can be corrected by supplementing its precursors glycine and cysteine (provided as N-acetylcysteine, NAC), with the combination termed GlyNAC.

This randomized clinical trial will evaluate the effect of GlyNAC vs. alanine placebo supplementation provided for 24-weeks to patients with AD, and measure changes in cognition, GSH concentrations, oxidative stress, brain glucose uptake, brain inflammation and insulin resistance.

Participants who are positive for a beta-amyloid PET scan and meeting cognitive screening criteria will be recruited, and enrolled only after meeting eligibility criteria. Before beginning study supplementation they will undergo imaging studies (MRI, FDG-PET and TSPO-PET scans), and only the FDG- and TSPO-PET scans will be repeated after completing 24-weeks of nutrient supplementation. Cognitive measurements, metabolic and mitochondrial measurements (as described below) will be done before supplementation, and after 12-weeks and 24-weeks of completing supplementation.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age 55-85 years;
  • Gradual and progressive memory loss for more than 1 year, with a Montreal Cognitive Assessment score of 10-20;
  • Amyloid positivity on PET scan;
  • Availability of a study partner.

Exclusion criteria

  • hospitalization in past 3 months;
  • use of insulin medications;
  • untreated thyroid disease;
  • creatinine levels >1.5 mg/dL;
  • hemoglobin concentration <11.0 g/dL;
  • known liver disease, or AST/ALT level >2x ULN;
  • history of stroke, brain tumor, active heart failure or active cancer (removable basal cell cancers will not be an exclusion criteria);
  • untreated depression or other severe psychiatric disorders;
  • pregnancy or nursing (unlikely in this population)

Treatment and study plan

Glycine

Dietary Supplement

The active arm will supplement a combination of glycine and N-acetylcysteine (GlyNAC)

N-acetylcysteine

Dietary Supplement

The active arm will supplement a combination of glycine and N-acetylcysteine (GlyNAC)

Alanine

Dietary Supplement

The placebo arm will supplement Alanine

Primary outcomes

  1. Cognition

    Time frame: Day 0 of supplementation, and 12-weeks and 24-weeks after starting supplementation

    Measured using ADAS-Cog testing

  2. Brain glucose uptake

    Time frame: Done before supplementation and 24-weeks after starting supplementation

    Measured using brain FDG-PET scan

  3. Brain inflammation

    Time frame: Done before supplementation and 24-weeks after starting supplementation

    Done using brain TSPO-PET scan

Secondary outcomes

  1. Activities of daily living

    Time frame: Day 0 of supplementation, 12-weeks and 24-weeks after starting supplementation

    Measured using the ADCS-ADL scale

  2. Mitochondrial fuel oxidation

    Time frame: Day 0 of supplementation, 12-weeks and 24-weeks after starting supplementation

    Measured using indirect calorimetry in the fasted and post-glucose fed state

  3. Red-blood cell glutathione, glycine, cysteine and glutamic aid

    Time frame: Day 0 of supplementation, 12-weeks and 24-weeks after starting supplementation

    Measured using UPLC

  4. Oxidative stress

    Time frame: Day 0 of supplementation, 12-weeks and 24-weeks after starting supplementation

    Measured as plasma concentrations of TBARS and malondialdehyde

  5. Damage due to oxidative stress

    Time frame: Day 0 of supplementation, 12-weeks and 24-weeks after starting supplementation

    Measured as plasma concentration of isoprostanes

  6. Inflammatory cytokines

    Time frame: Day 0 of supplementation, 12-weeks and 24-weeks after starting supplementation

    Measured as plasma concentrations of IL6, TNFa

  7. Endothelial dysfunction

    Time frame: Day 0 of supplementation, 12-weeks and 24-weeks after starting supplementation

    Measured as plasma concentrations of sICAM1, sVCAM1, E-selectin

  8. Plasma concentration of Brain-derived neurotropic factor (BDNF)

    Time frame: Day 0 of supplementation, 12-weeks and 24-weeks after starting supplementation

    Measured using an ELISA kit

  9. Mitochondrial energetics

    Time frame: Day 0 of supplementation, 12-weeks and 24-weeks after starting supplementation

    Measured using the Oroboros high-resolution respirometer

Study contacts

Contact information is provided by the study sponsor or research team.

Rajagopal V Sekhar, M.D.

CONTACT

[email protected]

7137983908

Sponsors and collaborators

Lead sponsor

Baylor College of Medicine

Other

Collaborators

  • The Methodist Hospital Research Institute

Registry information

Important dates

Study start
2022
Primary completion
2026
Study completion
2026
First posted
Feb 5, 2021
Registry last updated
Jun 10, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.